Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

Authors Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli

Published 8 February 2009 Volume 2009:5 Pages 233—242

DOI http://dx.doi.org/10.2147/VHRM.S4800

Review by Single-blind

Peer reviewer comments 4

Alessandra Del Fiorentino, Silvana Cianchetti, Alessandro Celi, Giulia Dell’Omo, Roberto Pedrinelli

Dipartimento Cardio Toracico e Vascolare, Università di Pisa, Italy

Abstract: Anti-inflammatory properties may contribute to the pharmacological effects of angiotensin II receptor blockers (ARBs), a leading therapeutic class in the management of hypertension and related cardiovascular and renal diseases. That possibility, supported by consistent evidence from in-vitro and animal studies showing pro-inflammatory properties of angiotensin II, has been evaluated clinically by measuring the effect of ARBs on C-reactive protein and other circulating indices of inflammation (e-selectin, adhesion molecules, interleukin-6, tissue necrosis factor-alpha, monocyte chemoattractant protein-1) of potential clinical relevance, a body of evidence that this paper aims to review.

Keywords: renin–angiotensin system, angiotensin II type 1 receptor blockers, vascular inflammation, C-reactive protein, circulating inflammatory markers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Lack of a relationship between circulating gamma-glutamyltransferase levels and carotid intima media thickness in hypertensive and diabetic patients

Nuti M, Spontoni P, Grigoratos C, Dell'Omo G, Balbarini A, Pedrinelli R

Vascular Health and Risk Management 2012, 8:275-281

Published Date: 1 May 2012

Readers of this article also read:

The clinical use of regenerative therapy in COPD

Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1389-1396

Published Date: 12 December 2014

Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US

Marrett E, Zhao C, Zhang NJ, Zhang Q, Ramey DR, Tomassini JE, Tershakovec AM, Neff DR

Vascular Health and Risk Management 2014, 10:237-246

Published Date: 25 April 2014

Trabeculectomy with double low dose of mitomycin C – two years of follow-up

Errico D, Scrimieri F, Riccardi R, Fedeli R, Iarossi G

Clinical Ophthalmology 2011, 5:1679-1686

Published Date: 1 December 2011

Validation of four automatic devices for self-measurement of blood pressure according to the international protocol of the European Society of Hypertension

Topouchian J, Agnoletti D, Blacher J, Youssef A, Ibanez I, Khabouth J, Khawaja S, Beaino L, Asmar R

Vascular Health and Risk Management 2011, 7:709-717

Published Date: 30 November 2011

Olmesartan/amlodipine: a review of its use in the management of hypertension

Kreutz R

Vascular Health and Risk Management 2011, 7:183-192

Published Date: 29 March 2011

Role of endothelin receptor A and NADPH oxidase in vascular abnormalities

De-Zai Dai, Yin Dai

Vascular Health and Risk Management 2010, 6:787-794

Published Date: 3 September 2010

Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update

Maurizio Destro, Francesca Cagnoni, Antonio D’Ospina, et al

Vascular Health and Risk Management 2010, 6:253-260

Published Date: 14 April 2010

The evolving role of alemtuzumab (Campath-1H) in renal transplantation

Phuong-Thu T Pham, Gerald S Lipshutz, Phuong-Truc T Pham, Joseph Kawahji, Jennifer S Singer, Phuong-Chi T Pham

Drug Design, Development and Therapy 2009, 3:41-49

Published Date: 23 December 2008

The influence of polymorbidity, revascularization, and wound therapy on the healing of arterial ulceration

Joerg Tautenhahn, Ralf Lobmann, Brigitte Koenig, Zuhir Halloul, Hans Lippert, Thomas Buerger

Vascular Health and Risk Management 2008, 4:683-689

Published Date: 6 June 2008